MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2017 International Congress

    Quality of Life in Homebound People with Advanced Parkinson’s Disease: Feasibility and Outcomes of an Interdisciplinary Home Visit Program

    J. Fleisher, M. Sweeney, S. Oyler, A. Lemen, A. Fazl, M. Ko, T. Meisel, N. Friede, G. Dacpano, R. Gilbert, A. Di Rocco, J. Chodosh (New York, NY, USA)

    Objective: 1) To demonstrate the feasibility of an interdisciplinary home visit program (HVP) for advanced Parkinson’s disease (PD) providing expert, interdisciplinary care directly to homebound…
  • 2017 International Congress

    Changes in Functioning Associated with Exercise in Individuals with Parkinson’s

    L. Clack, B. Riemann, M. Cohen (Savannah, GA, USA)

    Objective: The purpose of this study was to assess changes in physical function, cognitive function, and quality of life in individuals with Parkinson’s disease as…
  • 2017 International Congress

    SweetSpot of antidystonic effect in pallidal neurostimulation: a European multicentre imaging study

    M. Reich, L. Lange, J. Roothans, A. Horn, F. Wodarg, J. Runge, M. Aström, F. Steigerwald, K. Witt, R. Nickl, P. Plettig, M. Wittstock, V. Coenen, P. Mahlknecht, W. Poewe, W. Eisner, C. Matthies, A. Kühn, J. Krauss, G. Deuschl*, J. Volkmann* (Wuerzburg, Germany)

    Objective: We investigated Volumes of Tissue activated (VTA) in dystonia subjects under DBS. We aimed to disentangle the SweetSpot for dystonia suppression within the pallidal region.…
  • 2017 International Congress

    Safety and tolerability of deep brain stimulation in early stage Parkinson’s disease: Five-year follow-up of medication use and adverse events

    A. Currie, M. Turchan, L. Heusinkveld, S. Millan, M. Hacker, A. Molinari, C. Gill, T. Davis, P. Konrad, F. Phibbs, P. Hedera, D. Charles (Memphis, TN, USA)

    Objective: To evaluate the long-term safety and tolerability of subthalamic nucleus deep brain stimulation (DBS) for early stage Parkinson’s disease (PD). Background: Twenty-nine subjects with…
  • 2017 International Congress

    Deep Brain Stimulation for Parkinson’s disease: Short-term outcomes, referral patterns and health disparities.

    D. Di Luca, V. Aldahondo, W. Jermakowicks, L. Segala, H. Moore, C. Singer, B. Levin, J. Jagid, C. Luca (Miami, FL, USA)

    Objective: To describe the practice patterns at University of Miami (UM), short term outcomes and health disparities among ethnic groups. Background: Deep brain stimulation (DBS)…
  • 2017 International Congress

    UPDRS benefit from dual frequency DBS fields sculpted by intentionally overlapped interleaving

    Y. Fernandez, D. Caputo, D. Schneider, R. Dipaola, S. Danish, E. Hargreaves (New York, NY, USA)

    Objective: We show that UPDRS-III scores after interleaving compared to those prior to interleaving reflect a gain in benefit by lowered scores. Background: Previously, we…
  • 2017 International Congress

    Factors determining the motor outcome of STN DBS in PD patients: Evidence for Dual Actions

    C. Lee, E.J. Choi, S.-C. Park, J.K. Lee (Seoul, Republic of Korea)

    Objective: We investigated factors determining the motor outcome of STN DBS in patients with Parkinson disease (PD). Background: The STN DBS has revolutionized the management…
  • 2017 International Congress

    Baseline characteristics associated with greatest improvement in HRQL after DBS surgery

    P. Schmidt, F. Cubillos, C. Martinez-Rubio, K. Lyons, C. Marras, T. Davis, E. Nelson, M. Okun (Miami, FL, USA)

    Objective: To determine the characteristics of DBS candidates associated with the greatest improvement in HRQL outcomes after surgery. Background: Site reviews of expert DBS centers…
  • 2017 International Congress

    Off-Target Implications of Nurr1 Agonist Therapy in Parkinson’s disease

    K. Steece-Collier, T. Collier, J. Stancati, C. Kemp, B. Daley, C. Sortwell (Grand Rapids, MI, USA)

    Objective: To examine the impact of Nurr1 agonists on regulation of striatal Nurr1 and levodopa (LD)-induced dyskinesias (LIDs) in a rat model of Parkinson’s disease…
  • 2017 International Congress

    Addressing Involuntary Movements in Tardive Dyskinesia (AIM-TD): Efficacy, Safety, and Tolerability of Fixed-Dose Deutetrabenazine for the Treatment of Tardive Dyskinesia

    K. Anderson, D. Stamler, M. Davis, S. Factor, R. Hauser, J. Isojärvi, J. Jimenez-Shahed, W. Ondo, H. Fernandez (Washington, DC, USA)

    Objective: To evaluate the efficacy, safety, and tolerability of deutetrabenazine in patients with tardive dyskinesia (TD). Background: AIM-TD is the second large 12-week, Phase III,…
  • « Previous Page
  • 1
  • …
  • 113
  • 114
  • 115
  • 116
  • 117
  • …
  • 155
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • #24970 (not found)
  • Life expectancy with and without Parkinson’s disease in the general population
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • An atypical and interesting feature of Parkinson´s disease
  • Effect of marijuana on Essential Tremor: A case report
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley